Description: Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.
Home Page: www.relieftherapeutics.com
BAtiment F2/F3
Geneva,
1202
Switzerland
Phone:
41 44 723 59 59
Officers
| Name | Title |
|---|---|
| Mr. Jack Weinstein M.B.A. | Chief Exec. Officer |
| Mr. Paolo Galfetti | COO & Director |
| Mr. Jeremy Meinen C.P.A. | Chief Accounting Officer, CFO & VP of Admin. |
| Dr. Nermeen Varawalla DPhil, M.B.A., M.D., MBA, Ph.D. | Chief Medical Officer |
| Mr. Marco Marotta | Chief Bus. Officer |
| Mr. Anthony M. Kim | Sr. VP & Head of U.S. Commercial Operations |
| Mr. Christopher Wick | Sr. Director & Head of U.S. Sales |
| Ms. Drew Cronin-Fine | Exec. Director & Head of U.S. Marketing |
| Dr. Serene Forte M.P.H., Ph.D. | Sr. VP & Head of Genetic Medicine |
| Mr. David McCullough | Sr. Director & Head of U.S. Market Access |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 1.1812 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.761 |
| Price-to-Sales TTM: | 18.8083 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |